ClinicalTrials.gg
RecruitingNCT05549258Updated Dec 5, 2025

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

A Phase 2 interventional study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder, sponsored by Amgen. Recruiting at 19 sites in 11 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 52 studies in Neuromyelitis Optica with a site in United States — 16 open to participants now, 21 under way, 2 of them phase 3. Neuromyelitis Optica · United States.

Planned enrollment
24th of 37
15 · median 22
Started
2023
with 3 others
Phase 2
7 of 52
2 open now
Primary completion
2027-04
later than 6 of 20 live
Registered
39th of 52
by date
Lead sponsor
3 of 52
Amgen

Among the 52 studies in Neuromyelitis Optica with a site in United States, this one is the 24th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2023, is one of 7 in phase 2, reaches primary completion later than 6 of the 20 other live ones, and was the 39th registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

16 of the 52 studies in Neuromyelitis Optica with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Neuromyelitis Optica with a site in United States, or all of them as a file.
02

Study summary

A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to \< 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin [Ig]G).

Read the detailed description

Approximately 15 participants to be enrolled and receive Inebilizumab administered intravenously over 28 weeks. The maximum trial duration per participant is approximately 80 weeks, including up to 4 week screening period, 9 visits during a 28 week open-label treatment period, and approximately 4 visits during a 52 week follow-up period. Safety evaluations will be performed regularly throughout the course of the study.

Acquired from Horizon in 2023.

03

Conditions studied

  • Neuromyelitis Optica Spectrum Disorder

Browse trials for

Keywords

  • NMOSD
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants, minimum body weight of 15 kg, age 2 to \< 18 years at the time of screening.
  • Positive serum anti-AQP4-IgG result at screening and diagnosed with NMOSD according to the criteria of Wingerchuk et al, 2015.
  • Documented history of one or more NMOSD acute relapses within the last year, or 2 or more NMOSD acute relapses within 2 years prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Any condition that, in the opinion of the Investigator, would interfere with the evaluation or administration of the Product or interpretation of participant safety or study results.
  • Concurrent/previous enrollment in another clinical study involving an investigational treatment within 4 weeks or 5 published half-lives of the investigational treatment, whichever is the longer, prior to Day 1.
  • Evidence of significant hepatic, renal, or metabolic dysfunction or significant hematological abnormality (one repeat test may be conducted to confirm results within the same screening period).
  • B-cell counts \< one-half of the lower limit of normal (LLN) for age according to the central laboratory.
  • Receipt of the following at any time prior to Day 1:

    1. Alemtuzumab
    2. Total lymphoid irradiation
    3. Bone marrow transplant
    4. T-cell vaccination therapy
  • Receipt of rituximab or any experimental B-cell depleting agent within 6 months prior to screening unless B-cell counts have returned to ≥ one-half the LLN.
  • Receipt of intravenous immunoglobulin (IVIG) within one month prior to Day 1.
  • Receipt of any of the following within 2 months prior to Day 1:

    1. Cyclosporine
    2. Methotrexate
    3. Mitoxantrone
    4. Cyclophosphamide
    5. Tocilizumab
    6. Satralizumab
    7. Eculizumab
  • Receipt of natalizumab (Tysabri®) within 6 months prior to Day 1.
  • Severe drug allergic history or anaphylaxis to 2 or more food products or medicine (including known sensitivity to acetaminophen/paracetamol, diphenhydramine or equivalent antihistamine, and methylprednisolone or equivalent ).
  • Diagnosed with a concurrent disease that is uncontrolled (unless approved by the medical monitor).
  • Recent receipt of live/attenuated vaccine or blood transfusion.

Receipt of any of the following:

  1. Any live or attenuated vaccine within 4 weeks prior to Day 1 (administration of killed vaccines and nucleoside-modified mRNA-based vaccines is acceptable; the Sponsor recommends that Investigators ensure all participants are up to date on required vaccinations prior to study entry).
  2. Bacillus Calmette Guérin vaccine within one year of screening.
  3. Blood transfusion within 4 weeks prior to screening or during screening.

    • serious active or chronic viral, bacterial, or fungal infection that requires treatment with anti-infectives, hospitalization, or, in the Investigator's opinion, represents an additional risk to the participant, within 2 months prior to Day 1.
    • Known history of congenital or acquired immunodeficiency (e.g., due to [HIV] infection, splenectomy, -related or idiopathic T-cell deficiencies) that predisposes the participant to infection.
    • Positive test for chronic infection at screening, defined as either:

a. Positive hepatitis B surface antigen (HBsAg), or b. Positive hepatitis B core (HBc) antibody (anti-HBc) plus negative hepatitis B surface (HBs) antibody (anti-HBs).

  • Positive test for virus antibody.
  • Negative test for varicella zoster virus (VZV)-IgG.
  • History of cancer, apart from squamous cell or basal cell carcinoma of the skin treated with documented success of curative therapy > 3 months prior to Day 1.
  • History of active or latent tuberculosis (TB), or a positive QuantiFERON®-TB Gold test at screening, unless treatment for TB was completed per local guidelines. Participants with latent TB or a positive QuantiFERON®-TB Gold test who are actively on anti-TB treatment can enroll if they have completed at least one month of anti-TB treatment and intend to complete the full course of anti-TB treatment. Participants with an indeterminate QuantiFERON®-TB Gold test result can enroll if a repeat QuantiFERON®-TB Gold test is negative or a tuberculin skin test is negative.
  • For participants who may undergo MRI scans:

    1. Unable to undergo an MRI scan (e.g., to Gd-containing MRI contrast agents, implanted pacemakers, defibrillators, or other metallic objects on or inside the body that limit performing MRI scans), or
    2. Unable to tolerate or comply with the MRI procedure.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Inebilizumab

    Infusion of Inebilizumab

    Drug: Inebilizumab

Interventions

  • Inebilizumab administered intravenously (IV) over a total of 28 weeks.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Inebilizumab

    Time frame: Day 1 to Week 28

  2. Area Under the Concentration Versus Time Curve of Inebilizumab from Time 0 to 14 Days Post-dose (AUC0-14d)

    Time frame: Day 1 to pre-dose on Day 15

  3. Area Under the Concentration Versus Time Curve of Inebilizumab from Time 0 Extrapolated to Infinity (AUC0-Inf)

    Time frame: Day 1 to Week 80

  4. Systemic Clearance (CL) of Inebilizumab

    Time frame: Day 1 to Week 80

  5. Terminal Elimination Half-life (t½) of Inebilizumab

    Time frame: Day 1 to Week 80

  6. Volume of Distribution at Steady State (VSS) of Inebilizumab

    Time frame: Day 1 to Week 80

  7. Change from Baseline in Peripheral Cluster of Differentiation (CD)20-positive B-cell Counts

    Time frame: Week 1, Week 2, Week 28, Week 80

  8. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)

    Time frame: Day 1 to Week 80

  9. Change from Baseline in Serum Chemistry

    Time frame: Week 1, Week 2, Week 28, Week 80

  10. Change from Baseline in Hematology

    Time frame: Week 1, Week 2, Week 28, Week 80

  11. Change from Baseline in Serum Immunoglobulins

    Time frame: Week 1, Week 2, Week 28, Week 80

  12. Change from Baseline in Systolic Blood Pressure

    Time frame: Week 1, Week 2, Week 28, Week 80

  13. Change from Baseline in Diastolic Blood Pressure

    Time frame: Week 1, Week 2, Week 28, Week 80

  14. Change from Baseline in Pulse Rate

    Time frame: Week 1, Week 2, Week 28, Week 80

  15. Change from Baseline in Respiratory Rate

    Time frame: Week 1, Week 2, Week 28, Week 80

  16. Change from Baseline in Body Temperature

    Time frame: Week 1, Week 2, Week 28, Week 80

Secondary outcomes

  1. Disease Activity: Time to First Relapse

    Time frame: Day 1 to Week 80

  2. Disease Activity: Proportion of Relapse-free Participants

    Time frame: Day 1 to Week 80

  3. Disease Activity: Annualized Relapse Rate

    Time frame: Day 1 to Week 80

  4. Health-Related Quality of Life (HRQoL) change from baseline in Euro Quality of Life-5 Dimension Youth score

    Change in baseline for the 5 dimensions: mobility, looking after myself, doing usual activities, having pain or discomfort, and feeling worried, sad, or unhappy. A higher score indicates onset or worsening of an affective disorder.

    Time frame: Day 1 to Week 80

  5. HRQoL change from baseline in Pediatric Quality of Life Inventory

    Change in baseline comprised from 4 generic core scales: Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning. A higher score indicates a better quality of life.

    Time frame: Day 1 to Week 80

  6. Visual Acuity change from baseline

    Time frame: Day 1 to Week 80

  7. Change From Baseline in Expanded Disability Status Scale

    Change in baseline comprised from results of 8 Functional Systems: Visual, Brainstem, Pryamidal, Cerebellar, Sensory, Bowel, Bladder, and Cerebral. A higher score indicates a higher grade of impairment and disability.

    Time frame: Day 1 to Week 80

  8. Anti-drug antibody (ADA) rate

    Time frame: Day 1 to Week 80

07

Study locations

19 of 19 sites recruiting
  • UCSD Altman Clinical and Translational Research Institute Building
    La Jolla, California 92037-1337, United States
    Recruiting
  • Loma Linda University Children's Hospital - PIN
    Loma Linda, California 92354, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
  • University of Texas Southwestern Medical Center
    Dallas, Texas 78701, United States
    Recruiting
  • Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan
    Parque Patricios, Ciudad Autónoma de BuenosAires C1245AAM, Argentina
    Recruiting
  • Hospital Santa Izabel-Rua Floriano Peixoto 300
    Salvador, Estado de Bahia 40050-410, Brazil
    Recruiting
  • Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)
    Porto Alegre/RS, 90610-000, Brazil
    Recruiting
  • CPQuali Pesquisa Clínica Sao Paulo
    São Paulo, 01228-000, Brazil
    Recruiting
  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, 05403-000, Brazil
    Recruiting
  • Hospital For Sick Children
    Toronto, Ontario M5G 1X8, Canada
    Recruiting
  • Centre Hospitalier Universitaire de Bicêtre
    Le Kremlin-Bicêtre, Val-de-Marne 94275, France
    Recruiting
  • Erasmus MC Sophia Children's Hospital-Wytemaweg 80
    Rotterdam, South Holland 3015 GD, Netherlands
    Recruiting
  • Uniwersyteckie Centrum Kliniczne w Gdansku - Smoluchowskiego 17
    Gdansk, 80-952, Poland
    Recruiting
  • Clinic for Neurology and Psychiatry for Children and Youth
    Belgrade, Belgrade 11000, Serbia
    Recruiting
  • Hospital Sant Joan de Deu - PIN
    Espluges de Llobregat, Barcelona 08950, Spain
    Recruiting
  • Karolinska Universitetssjukhuset Solna
    Stockholm, Stockholm County 17176, Sweden
    Recruiting
  • Evelina London Children's Hospital
    London, London, City of SE1 7EH, United Kingdom
    Recruiting
  • Great Ormond Street Hospital - PPDS
    London, London, City of WC1N 3JH, United Kingdom
    Recruiting
  • Birmingham Women's and Children's NHS Foundation Trust
    Birmingham, West Midlands B4 6NH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Apr 2027, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2022
First posted
Sep 22, 2022
StartActual
Jul 3, 2023
Primary completionEst.
Apr 13, 2027
CompletionEst.
Apr 13, 2027
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05549258
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 22, 2022
Start date
Jul 3, 2023
Primary completion
Apr 13, 2027 (estimated)
Completion
Apr 13, 2027 (estimated)
Last update
Dec 5, 2025

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion